News

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

This September 22 Savvy Conversations episode features a conversation on vitiligo and its impact on patients of diverse skin types.

Phase 3 STRIVE-ON Safety Trial results were presented at the 2025 Neurocritical Care Society annual meeting and suggest GTx-104’s viability over oral nimodipine.

Cytisinicline shows promise as a safe and effective smoking cessation treatment, significantly improving quit rates in COPD.

Neuen reviews recent advances in IgAN treatment and findings from a systematic review and meta-analysis guiding their use in clinical practice.

A significant amount of TED cases go undiagnosed due to a lack of routine screening – Khachikian discusses what is needed to address this problem.

Research suggests emergency department–discharged children rarely return within 7 days, questioning routine corticosteroid use for mild-to-moderate reactions.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

New findings from the POSITIVE trial highlight tildrakizumab's effectiveness in enhancing quality of life for psoriatic disease patients.

Weidinger discusses results from a pair of late-breaking presentations on temtokibart in atopic dermatitis from EADV 2025.

New data reveals ritlecitinib's long-term efficacy for alopecia areata, showing sustained hair regrowth in 30% of patients after 3 years.

In this interview at EADV, Hong speaks about his team’s findings on IL-22RA1 antagonism with temtokibart and its impact on atopic dermatitis.

Adolescents with alopecia areata show promising treatment responses, highlighting the need for diverse therapeutic options to improve outcomes.

This interview segment with Bunick at EADV highlights some of the significance of these recent findings on cardiovascular risk and upadacitinib use over 6 years.

These late-breaking data at EADV highlight the impacts of ATI-2138, an oral small-molecule ITK/JAK3 inhibitor, on atopic dermatitis.

The approval offers the flexibility of self-administration from the start of treatment for UC, building on the prior approval of SC induction in Crohn’s disease.

Chapman discussed further research to be done with PDT for basal cell carcinoma.

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

The guideline offers 12 conditional recommendations for the diagnosis and management of gastroparesis, emphasizing individualized care and calling for more research.

Investigators formulated a series of hypothetical situations to test the overall economic impact of introducing lonapegsomatropin into the growth hormone market.

In this EADV interview, Bunick touches on his team’s findings related to risk of VTE, MACE, and malignancy in patients with atopic dermatitis treated with upadacitinib for 6 years.

Janovsky describes the importance of early identification, the new treatment options available for MASH, and the continued importance of diet and exercise.

In this analysis, the long-term cardiovascular safety of upadacitinib treatment for atopic dermatitis was highlighted.

These new data, presented at EADV, highlight remibrutinib’s impact on specific IgG autoantibody levels in individuals with chronic spontaneous urticaria (CSU).

Le describes growing multidisciplinary conversations around CKM and why cardiovascular health needs to be a central focus of MASH/MASLD care.

This EADV interview featured a discussion with Brittany Craiglow, MD, on the topic of developments in the field of alopecia areata treatment.

New data reveals ritlecitinib's long-term effectiveness for alopecia areata, showing significant hair regrowth and sustained benefits in patients.

Chapman discussed the latest findings from a phase 3 study assessing PDT with 10% ALA in people with BCC.